NASDAQ : ZBIO
Zenas BioPharma, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 28.76 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.87B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.79B |
| Enterprise Value | 1.44B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 65.18M |
| Shares Outstanding | 65.18M |
| Shares Change (YoY) | +60.52% |
| Shares Change (QoQ) | +13.46% |
| Owned by Insiders (%) | 1.52% |
| Owned by Institutions (%) | 95.20% |
| Float | 45.02M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,850.37 |
| Forward PS | 35.88 |
| PB Ratio | 7.28 |
| P/TBV Ratio | 7.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1,505.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.93 |
| Quick Ratio | 9.78 |
| Debt / Equity | 1.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.29 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -199.04% |
| Return on Assets (ROA) | -34.42% |
| Return on Invested Capital (ROIC) | -43.58% |
| Return on Capital Employed (ROCE) | -43.07% |
| Weighted Average Cost of Capital (WACC) | 0.38% |
| Revenue Per Employee | $5,988 |
| Profits Per Employee | -$2.90M |
| Employee Count | 167 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 220,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.88 |
| 52-Week Price Change | -9.15% |
| 50-Day Moving Average | 29.40 |
| 200-Day Moving Average | 25.00 |
| Relative Strength Index (RSI) | 52.32 |
| Average Volume (20 Days) | 456,472 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 12.54M |
| Short Previous Month | 11.94M |
| Short % of Shares Out | 19.24% |
| Short % of Float | 27.85% |
| Short Ratio (days to cover) | 17.28 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.00M |
| Gross Profit | -212.47M |
| Operating Income | -273.90M |
| Pretax Income | -484.16M |
| Net Income | -484.38M |
| EBITDA | -273.87M |
| EBIT | -273.90M |
| Loss Per Share | -$9.05 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 643.13M |
| Total Debt | 297.86M |
| Net Cash | 345.27M |
| Net Cash Per Share | $5.30 |
| Equity (Book Value) | 247.10M |
| Book Value Per Share | 3.90 |
| Working Capital | 587.98M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -225.97M |
| Capital Expenditures | -2,000 |
| Depreciation & Amortization | 31,000 |
| Net Borrowing | 296.60M |
| Free Cash Flow | -225.97M |
| FCF Per Share | -$3.47 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -27,390.10% |
| Pretax Margin | -48,416.40% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -60.52% |
| Shareholder Yield | -60.52% |
| Earnings Yield | -32.98% |
| FCF Yield | -12.21% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $47.88 |
| Price Target Difference | 74.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 143.70% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.6 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |